InsiderSignal.AI

InsiderSignal.ai

RCKT - Rocket Pharmaceuticals, Inc.

Insider Purchase by Bjork Elisabeth (Dir)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

1 month ago, Bjork Elisabeth, serving as Dir at Rocket Pharmaceuticals, Inc. (RCKT), purchased 10,000 shares at $3.44 per share, for a total transaction value of $34,400.00. Following this transaction, Bjork Elisabeth now holds 50,000 shares of RCKT.

This purchase represents a 25.00% increase in Bjork Elisabeth's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, January 2, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, January 6, 2026, 4 days after the trade was made.

Rocket Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Bjork Elisabeth

Bjork Elisabeth

Dir

Elisabeth Björk, M.D., Ph.D. is an accomplished pharmaceutical executive and independent director at Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), where she recently purchased 10,000 shares on August 27, 2025, at $3.44 per share.[[4]](https://www.ainvest.com/news/rocket-pharmaceuticals-director-bjork-elisabeth-buys-10-000-shares-3-44-share-2601/)[[5]](https://www.tradingview.com/news/tradingview:8dcc22136c220:0-rocket-pharmaceuticals-director-elisabeth-bjork-buys-10-000-shares/) With over 30 years of experience in clinical practice, academic research, and drug development, she previously held senior leadership roles at AstraZeneca, including Senior Vice President and Head of the Obesity franchise, as well as Head of Late-stage Development for Cardiovascular, Renal, and Metabolism (CVRM) R&D, where she advanced blockbuster drugs and transformed the CVRM portfolio.[[1]](https://www.nodthera.com/news/nodthera-announces-appointment-of-elisabeth-bjork-as-board-member/)[[2]](https://www.camurus.com/about-us/board-of-directors/elisabeth-bjork/)[[3]](https://rocketpharma.com/about-us) Dr. Björk serves on the boards of multiple public and private biotech companies, including Pharvaris N.V. (NASDAQ: PHVS), Vicore Pharma AB (STO: VICO), Camurus AB (STO: CAMX), and NodThera, leveraging her expertise in cardiometabolic diseases, regulatory submissions, and commercialization.[[1]](https://www.nodthera.com/news/nodthera-announces-appointment-of-elisabeth-bjork-as-board-member/)[[2]](https://www.camurus.com/about-us/board-of-directors/elisabeth-bjork/) An endocrinologist by training, she earned her M.D. from the Karolinska Institute and a Ph.D. in Endocrinology from Uppsala University, where she also served as Associate Professor of Medicine.[[1]](https://www.nodthera.com/news/nodthera-announces-appointment-of-elisabeth-bjork-as-board-member/)[[2]](https://www.camurus.com/about-us/board-of-directors/elisabeth-bjork/)

View full insider profile →

Trade Price

$3.44

Quantity

10,000

Total Value

$34,400.00

Shares Owned

50,000

Trade Date

Friday, January 2, 2026

51 days ago

SEC Filing Date

Tuesday, January 6, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Rocket Pharmaceuticals, Inc.

Company Overview

No company information available
View news mentioning RCKT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/2881175

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime